These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1141 related articles for article (PubMed ID: 19493466)

  • 1. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
    Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
    Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
    Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].
    Zhang NH; Zhang XS; Li J; Zhang RH; Gao YF; Zeng MS
    Ai Zheng; 2006 May; 25(5):566-9. PubMed ID: 16687075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients.
    Whitney BM; Chan AT; Rickinson AB; Lee SP; Lin CK; Johnson PJ
    J Med Virol; 2002 Jul; 67(3):359-63. PubMed ID: 12116028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
    Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
    AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
    Ling W; Cao SM; Huang QH; Li YH; Deng MQ
    Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
    Liu MT; Yeh CY
    Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Quantitative analysis of Epstein-Barr virus DNA in plasma and peripheral blood cells in patients with nasopharyngeal carcinoma].
    Zhang Y; Gao HY; Feng HX; Deng L; Huang MY; Hu B; Cheng G; Wu QL; Cui NJ; Shao JY
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(12):982-6. PubMed ID: 15312530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma.
    Shao JY; Zhang Y; Li YH; Gao HY; Feng HX; Wu QL; Cui NJ; Cheng G; Hu B; Hu LF; Ernberg I; Zeng YX
    Anticancer Res; 2004; 24(6):4059-66. PubMed ID: 15736452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and analysis of anti-latent membrane protein 2A antibodies in the sera of patients with Epstein-Barr virus associated malignancies.
    Chen Y; Yao K; Sun H; Qing J; Peng GY
    Chin Med J (Engl); 2005 May; 118(9):725-30. PubMed ID: 15899133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
    Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
    Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined determination of Epstein-Barr virus-related antibodies and antigens for diagnosis of nasopharyngeal carcinoma.
    Luo YL; Ou GP; Chi PD; Liang YN; Liu YH; Huang MY
    Ai Zheng; 2009 Jan; 28(1):76-8. PubMed ID: 19448423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
    Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
    Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
    Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity and specificity of Epstein-Barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review.
    Tsang RK; Vlantis AC; Ho RW; Tam JS; To KF; van Hasselt CA
    Head Neck; 2004 Jul; 26(7):598-602. PubMed ID: 15229902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.